Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG168

—

8cf9a595-7a4c-5a6e-b1fb-8bd7be3e6188

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.498
  • G2M_CHECKPOINT+0.466
  • MYC_TARGETS_V1+0.455
  • OXIDATIVE_PHOSPHORYLATION+0.388
  • HEDGEHOG_SIGNALING+0.356
  • PROTEIN_SECRETION+0.303
  • ANDROGEN_RESPONSE+0.290
  • MITOTIC_SPINDLE+0.276
  • UNFOLDED_PROTEIN_RESPONSE+0.268
  • SPERMATOGENESIS+0.251

Top 10 suppressed

  • TNFA_SIGNALING_VIA_NFKB-0.477
  • IL6_JAK_STAT3_SIGNALING-0.418
  • ALLOGRAFT_REJECTION-0.386
  • INFLAMMATORY_RESPONSE-0.370
  • APOPTOSIS-0.271
  • CHOLESTEROL_HOMEOSTASIS-0.263
  • INTERFERON_GAMMA_RESPONSE-0.249
  • COAGULATION-0.217
  • MYOGENESIS-0.214
  • HYPOXIA-0.210

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1TCGA-A2-A0YG-01A-21R-A109-07
breast-umap@18
—C0.877
2SJEPD030743_D1.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.858
3SJEPD030833_D1.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.839
4E3E4E7DA-AD14-44BA-B3BE-02652B3CEE18
brain-umap@2
——0.829
5ERR2598102
medullo-epn-umap@date-based
fetalfetal0.827
64D9EF242-9F58-4681-ADCF-556E05932931
brain-umap@2
——0.827
7ERR2598196
medullo-epn-umap@date-based
fetalfetal0.824
8E3A67B7B-7427-4C11-912B-166451072767
brain-umap@2
——0.823
9BS_7G42J2SK
medullo-epn-umap@date-based
EPNSupratentorial EPN0.820
10BS_QXKRN6CR
medullo-epn-umap@date-based
EPNSupratentorial EPN0.819

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.498Inavolisib— uncovered
G2M_CHECKPOINT0.466Inavolisib— uncovered
MYC_TARGETS_V10.455Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.388Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.356Inavolisib— uncovered
PROTEIN_SECRETION0.303Remibrutinib— uncovered
ANDROGEN_RESPONSE0.290Inavolisib— uncovered
MITOTIC_SPINDLE0.276Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.268Idelalisib— uncovered
SPERMATOGENESIS0.251Inavolisib— uncovered
DNA_REPAIR0.239Idelalisib— uncovered
PEROXISOME0.235Idelalisib— uncovered
GLYCOLYSIS0.214Inavolisib— uncovered
NOTCH_SIGNALING0.205Inavolisib— uncovered
UV_RESPONSE_DN0.165Inavolisib— uncovered
ADIPOGENESIS0.132Inavolisib— uncovered
MYC_TARGETS_V20.114Idelalisib— uncovered
MTORC1_SIGNALING0.107Inavolisib— uncovered
FATTY_ACID_METABOLISM0.103Inavolisib— uncovered
HEME_METABOLISM0.101Temsirolimus— uncovered